aTyr Pharma, Inc.
ATYR
$4.05
$0.061.50%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -47.89% | -28.51% | -19.48% | -11.14% | 6.96% |
| Total Depreciation and Amortization | -35.73% | 4.12% | 28.07% | 61.71% | 129.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -174.65% | -148.62% | -138.25% | -122.59% | -91.83% |
| Change in Net Operating Assets | -168.06% | -223.14% | -135.55% | 1,902.16% | 163.55% |
| Cash from Operations | -106.13% | -80.00% | -70.01% | 20.69% | 17.86% |
| Capital Expenditure | 98.93% | 88.45% | -4.99% | -156.86% | -884.63% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | 50.00% | -91.62% | -93.45% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 234.42% | 294.04% | 823.06% | -132.70% | -708.34% |
| Cash from Investing | 214.44% | 240.11% | 400.54% | -142.60% | -776.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -40.29% | -97.05% | -240.15% | -496.97% | -- |
| Issuance of Common Stock | -55.17% | -50.86% | -53.52% | 1,107.61% | 1,239.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -55.72% | -51.43% | -54.24% | 1,115.01% | 1,239.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.57% | -192.57% | -189.08% | 19.17% | 81.20% |
